These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11067647)

  • 41. Academic investigator-initiated trials and the challenge of sponsor responsibility: the Cologne Sponsor Model.
    Georgias C; Grunow A; Olderog M; May A; Paulus U
    Clin Trials; 2012 Dec; 9(6):781-7. PubMed ID: 23104975
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [How to establish GCP-units in Denmark?].
    Krogsgaard K; Andreasen PB
    Ugeskr Laeger; 2003 Apr; 165(16):1665-7. PubMed ID: 12756825
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Investigators' Brochure: a comparison of the draft international conference on harmonisation guideline with current Food and Drug Administration requirements.
    Cocchetto DM
    Qual Assur; 1995 Dec; 4(4):240-6. PubMed ID: 8890349
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Good Clinical Practice guideline and its interpretation - perceptions of clinical trial teams in sub-Saharan Africa.
    Vischer N; Pfeiffer C; Joller A; Klingmann I; Ka A; Kpormegbe SK; Burri C
    Trop Med Int Health; 2016 Aug; 21(8):1040-1048. PubMed ID: 27260671
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drugs, QTc interval prolongation and final ICH E14 guideline : an important milestone with challenges ahead.
    Shah RR
    Drug Saf; 2005; 28(11):1009-28. PubMed ID: 16231954
    [TBL] [Abstract][Full Text] [Related]  

  • 46. More than a box to check: Research sponsor and clinical investigator perspectives on making GCP training relevant.
    Swezey T; McGuire FH; Hurley P; Panhuis J; Goldstein K; Chuck T; Dombeck C; Perry B; Brennan C; Phrsai N; Corneli A
    Contemp Clin Trials Commun; 2020 Sep; 19():100606. PubMed ID: 32817904
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of clinical trials by Ethics Committees in Germany--results and a comparison of two surveys performed among members of the German Association of Research-Based Pharmaceutical Companies (vfa).
    Russ H; Busta S; Jost B; Bethke TD
    Ger Med Sci; 2015; 13():Doc02. PubMed ID: 25698912
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Points to Consider for Implementation of the ICH E17 Guideline: Learning from Past Multiregional Clinical Trials in Japan.
    Asano K; Aoi Y; Kamada S; Uyama Y; Tohkin M
    Clin Pharmacol Ther; 2021 Jun; 109(6):1555-1563. PubMed ID: 33245786
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and quality in clinical trials. Requirements to the investigator site. European Economic Community.
    Friederichs E; Spitzer SG; Bach R
    Arzneimittelforschung; 1994 Feb; 44(2):182-4. PubMed ID: 8147953
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Researchers' views of the acceptability of restrictive provisions in clinical trial agreements with industry sponsors.
    Mello MM; Clarridge BR; Studdert DM
    Account Res; 2005; 12(3):163-91. PubMed ID: 16634168
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Difficulties with conducting clinical trials in France].
    Zannad F; Plétan Y
    Therapie; 2001; 56(4):341-7. PubMed ID: 11677850
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Chapter 3. Transitions in clinical trials and appropriate use of drugs in Japan (1980-2010)].
    Koshimizu T
    Yakushigaku Zasshi; 2014; 49(1):50-63. PubMed ID: 25272637
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Practical issues and observations on the use of foreign clinical data in drug development.
    Goto M; Hamasaki T
    J Biopharm Stat; 2002 Aug; 12(3):369-84. PubMed ID: 12448578
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New Drugs and Clinical Trial Rules 2019, What is New? Our Views from Ethical Perspective.
    G S; Lc P
    J Assoc Physicians India; 2019 Oct; 67(10):75-76. PubMed ID: 31571459
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Regulatory changes after the enforcement of the new Clinical Trials Act in Japan.
    Nakamura K; Shibata T
    Jpn J Clin Oncol; 2020 Apr; 50(4):399-404. PubMed ID: 32125380
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.
    BioDrugs; 2003; 17(1):69-72. PubMed ID: 12534322
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Delays in new drug applications in Japan and industrial R&D strategies.
    Hirai Y; Kinoshita H; Kusama M; Yasuda K; Sugiyama Y; Ono S
    Clin Pharmacol Ther; 2010 Feb; 87(2):212-8. PubMed ID: 19940847
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Telecommunications, health and radiology: potential synergies for the new millennium].
    Lagalla R
    Radiol Med; 2001; 102(1-2):14-9. PubMed ID: 11677432
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Improving the infrastructure for clinical trials in Japan].
    Nakano S
    Gan To Kagaku Ryoho; 1999 Jan; 26(2 Suppl):225-30. PubMed ID: 9987523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.